- 中国科学论文统计源期刊
- 中国科技核心期刊
- 美国化学文摘(CA)来源期刊
- 日本科学技术振兴机构数据库(JST)
临床输血与检验 ›› 2022, Vol. 24 ›› Issue (5): 658-668.DOI: 10.3969/j.issn.1671-2587.2022.05.021
高明, 魏晴
收稿日期:2022-08-15
出版日期:2022-10-20
发布日期:2022-10-31
作者简介:高明（1989-）,湖北黄冈人,主管技师,博士,主要从事输血相关免疫调节的研究,（E-mail）191598480@qq.com。
Received:2022-08-15
Online:2022-10-20
Published:2022-10-31
摘要： 人凝血酶原复合物（prothrombin complex concentrate,PCC）是一种由来源于人血浆,主要含有维生素K依赖性凝血因子（FⅡ、FⅦ、FⅨ和FⅩ）的冻干蛋白粉。因其可快速逆转凝血因子缺乏导致的出血,被广泛应用于临床。然而,PCC在不同疾病中的应用存在差异,不合理应用可加大血栓形成的风险。为更好地应用PCC,本文综述了其临床应用新进展。
中图分类号:
高明, 魏晴. 人凝血酶原复合物的临床应用新进展[J]. 临床输血与检验, 2022, 24(5): 658-668.
| [1] VAN DEN BRINK D P,WIRTZ M R,NETO A S,et al. Effectiveness of prothrombin complex concentrate for the treatment of bleeding:a systematic review and meta-analysis[J]. J Thromb Haemost,2020,18(10):2457-2467. [2] KEY N S,NEGRIER C.Coagulation factor concentrates:past,present,and future[J]. Lancet,2007,370(9585):439-448. [3] 沈琦,郝杰,盛凤仙,等.国产冻干人凝血酶原复合物质量标准的研究[J].中国生化药物杂志,2004,24(3):150-153. [4] BERNTORP E,FISCHER K,HART D P,et al.Haemophilia[J]. Nat Rev Dis Primers,2021,7(1):45. [5] DOLAN G,BENSON G,DUFFY A,et al.Haemophilia B:where are we now and what does the future hold?[J]. Blood Rev,2018,32(1):52-60. [6] FASSEL H,MCGUINN C.Haemophilia:factoring in new therapies[J]. Br J Haematol,2021,194(5):835-850. [7] FERREIRA J,DELOSSANTOS M.The clinical use of prothrombin complex concentrate[J].J Emerg Med,2013,44(6):1201-1210. [8] TANAKA K A,SHETTAR S,VANDYCK K,et al.Roles of four-factor prothrombin complex concentrate in the management of critical bleeding[J].Transfus Med Rev,2021,35(4):96-103. [9] HANKE A A,JOCH C,GÖRLINGER K.Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N):a pharmacovigilance study[J]. Br J Anaesth,2013,110(5):764-772. [10] TANAKA K A,ESPER S,BOLLIGER D.Perioperative factor concentrate therapy[J]. Br J Anaesth,2013,111:i35-i49. [11] JONES G M,ERDMAN M J,SMETANA K S,et al.3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal in severe bleeding:a multicenter,retrospective,propensity-matched pilot study[J]. J Thromb Thrombolysis,2016,42(1):19-26. [12] SHAPIRO A D,MITCHELL I S,NASR S.The future of bypassing agents for hemophilia with inhibitors in the era of novel agents[J]. J Thromb Haemost,2018,16(12):2362-2374. [13] TJØNNFJORD G E,BRINCH L,GEDDE-DAHL T,et al. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX[J]. Haemophilia,2004,10(2):174-178. [14] RODGERS G M.Prothrombin complex concentrates in emergency bleeding disorders[J]. Am J Hematol,2012,87(9):898-902. [15] CAO H J,TIAN Q,HUANG Y,et al.Biochemical characterization of prothrombin complex concentrates in China[J]. Biologicals,2015,43(2):84-91. [16] ERDOES G,KOSTER A,ORTMANN E,et al.A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients[J]. Anaesthesia,2021,76(3):381-392. [17] SCHWEBACH A A,WAYBRIGHT R A,JOHNSON T J.Fixed-dose four-factor prothrombin complex concentrate for vitamin K antagonist reversal:does one dose fit all?[J]. Pharmacotherapy,2019,39(5):599-608. [18] ORTEL T L,NEUMANN I,AGENO W,et al.American Society of Hematology 2020 guidelines for management of venous thromboembolism:treatment of deep vein thrombosis and pulmonary embolism[J]. Blood Adv,2020,4(19):4693-4738. [19] BITONTI M T,RUMBARGER R L,ABSHER R K,et al.Prospective evaluation of a fixed-dose 4-factor prothrombin complex concentrate protocol for urgent vitamin K antagonist reversal[J]. J Emerg Med,2020,58(2):324-329. [20] WILLIS C M,HALL A B.Use of four-factor prothrombin complex concentrate in the emergency department:a review[J]. J Emerg Nurs,2015,41(1):9-12. [21] HUDA S A,KAHLOWN S,JILANI M H,et al.Management of life-threatening bleeding in patients with mechanical heart valves[J]. Cureus,2021,13(6):e15619. [22] LUKAS J G,REICHERT M J,JONES G M.Use of prothrombin complex concentrate in oral anticoagulant-associated major bleeding[J]. Crit Care Nurs Q,2022,45(2):167-179. [23] 国家食品药品监督管理局.关于人凝血酶原复合物等4种制品规程转正的通知[EB/OL].(2004-04-19).https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20040419010101210.html. [24] 湖南药事服务网.人凝血酶原复合物(PCC)[EB/OL].https://www.hnysfww.com/goods.php?id=3520. [25] GILBERT B W,MORTON L,HUFFMAN J B,et al.Modified version of the American College of Cardiology's recommendation for low-dose prothrombin complex concentrate is effective for warfarin reversal[J]. Am J Emerg Med,2020,38(4):806-809. [26] Daei M,Abbasi G,Khalili H,et al. Direct oral anticoagulants toxicity in children:an overview and practical guide[J]. Expert Opin Drug Saf,2022:2022 Aug 9;1-2022 Aug 910. [27] FRONTERA J A,LEWIN J J 3rd,RABINSTEIN A A,et al. Guideline for reversal of antithrombotics in intracranial hemorrhage:a statement for healthcare professionals from the neurocritical care society and society of critical care medicine[J]. Neurocrit Care,2016,24(1):6-46. [28] OSTERMANN H,VON HEYMANN C.Prothrombin complex concentrate for vitamin K antagonist reversal in acute bleeding settings:efficacy and safety[J]. Expert Rev Hematol,2019,12(7):525-540. [29] FAULKNER H,CHAKANKAR S,MAMMI M,et al.Safety and efficacy of prothrombin complex concentrate (PCC) for anticoagulation reversal in patients undergoing urgent neurosurgical procedures:a systematic review and metaanalysis[J]. Neurosurg Rev,2021,44(4):1921-1931. [30] MAKHOUL T,KELLY G,KERSTEN B,et al.Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal[J]. Thromb Res,2020,194:158-164. [31] BASKARAN J, LOPEZ R A, CASSAGNOL M.Prothrombin Complex Concentrate [M]. Treasure Island (FL): StatPearls Publishing. 2022. [32] PAGANO M B,FOROUTAN F,GOEL R,et al.Vitamin K antagonist reversal strategies:systematic review and network meta-analysis from the AABB[J]. Transfusion,2022,62(8):1652-1661. [33] LUTSEY P L,WALKER R F,MACLEHOSE R F,et al.Direct oral anticoagulants and warfarin for venous thromboembolism treatment:trends from 2012 to 2017[J]. Res Pract Thromb Haemost,2019,3(4):668-673. [34] NISHIMURA R A,OTTO C M,BONOW R O,et al.2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American college of cardiology/American heart association task force on clinical practice guidelines[J]. Circulation,2017,135(25):e1159-e1195. [35] CHEN A,STECKER E,WARDEN B A.Direct oral anticoagulant use:a practical guide to common clinical challenges[J]. J Am Heart Assoc,2020,9(13):e017559. [36] GUNASEKARAN K,RAJASURYA V,DEVASAHAYAM J,et al.A review of the incidence diagnosis and treatment of spontaneous hemorrhage in patients treated with direct oral anticoagulants[J]. J Clin Med,2020,9(9):2984. [37] WITT D M,CLARK N P,KAATZ S,et al.Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism[J]. J Thromb Thrombolysis,2016,41(1):187-205. [38] DEMEYERE R,GILLARDIN S,ARNOUT J,et al.Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery:a randomized study[J]. Vox Sang,2010,99(3):251-260. [39] SARODE R,MILLING T J Jr,REFAAI M A,et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding:a randomized,plasma-controlled,phase IIIb study[J]. Circulation,2013,128(11):1234-1243. [40] BAJDAS H,HANDZEL M,UTTARO E,et al.Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal[J]. Thromb Res,2022,214:76-81. [41] CICCI C D,WEISS A,DANG C,et al.Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage[J]. Pharmacotherapy,2022,42(5):366-374. [42] KOH H P,JAGAN N,GEORGE D,et al.The outcomes of three-factor prothrombin complex concentrate (3F-PCC) in warfarin anticoagulation reversal:a prospective,single-arm,open-label,multicentre study[J]. J Thromb Thrombolysis,2021,52(3):836-847. [43] CUKER A,BURNETT A,TRILLER D,et al.Reversal of direct oral anticoagulants:guidance from the Anticoagulation Forum[J]. Am J Hematol,2019,94(6):697-709. [44] VAN AART L,EIJKHOUT H W,KAMPHUIS J S,et al.Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy:an open,prospective randomized controlled trial[J]. Thromb Res,2006,118(3):313-320. [45] FRANCHINI M,FRATTINI F,CRESTANI S,et al.Haemophilia B:current pharmacotherapy and future directions[J]. Expert Opin Pharmacother,2012,13(14):2053-2063. [46] ABDOELLAKHAN R A,MIAH I P,KHORSAND N,et al.Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage:a retrospective analysis[J]. Neurocrit Care,2017,26(1):64-69. [47] STOECKER Z,VAN AMBER B,WOSTER C,et al.Evaluation of fixed versus variable dosing of 4-factor prothrombin complex concentrate for emergent warfarin reversal[J]. Am J Emerg Med,2021,48:282-287. [48] TOMASELLI G F,MAHAFFEY K W,CUKER A,et al.2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants:a report of the American college of cardiology solution set oversight committee[J]. J Am Coll Cardiol,2020,76(5):594-622. [49] BERSHAD E M,SUAREZ J I.Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage:a review of the literature[J]. Neurocrit Care,2010,12(3):403-413. [50] KING G S,COTTINGHAM L G,HUGHES R E,et al.Probable pulmonary embolism with repeat administration of prothrombin complex concentrate in a factor Xa inhibitor patient[J]. J Clin Pharm Ther,2018,43(6):903-905. [51] BARCELLONA D,FENU L,MARONGIU F.Point-of-care testing INR:an overview[J]. Clin Chem Lab Med,2017,55(6):800-805. [52] EERENBERG E S,KAMPHUISEN P W,SIJPKENS M K,et al.Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate:a randomized,placebo-controlled,crossover study in healthy subjects[J]. Circulation,2011,124(14):1573-1579. [53] KHORSAND N,KOOISTRA H A M,VAN HEST R M,et al. A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy[J]. Thromb Res,2015,135(1):9-19. [54] RUFF C T,GIUGLIANO R P,BRAUNWALD E,et al.Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials[J]. Lancet,2014,383(9921):955-962. [55] SMITH M N,DELONEY L,CARTER C,et al.Safety,efficacy,and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding:a retrospective study[J]. J Thromb Thrombolysis,2019,48(2):250-255. [56] CONNOLLY S J,CROWTHER M,EIKELBOOM J W,et al.Full study report of andexanet Alfa for bleeding associated with factor xa inhibitors[J]. N Engl J Med,2019,380(14):1326-1335. [57] POLLACK C V Jr,REILLY P A,EIKELBOOM J,et al. Idarucizumab for dabigatran reversal[J]. N Engl J Med,2015,373(6):511-520. [58] PANOS N G,COOK A M,JOHN S,et al.Factor xa inhibitor-related intracranial hemorrhage:results from a multicenter,observational cohort receiving prothrombin complex concentrates[J]. Circulation,2020,141(21):1681-1689. [59] DAGER W E,ROBERTS A J,NISHIJIMA D K.Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants[J]. Thromb Res,2019,173:71-76. [60] BERGER K,SANTIBAÑEZ M,LIN L N,et al. A low-dose 4F-PCC protocol for DOAC-associated intracranial hemorrhage[J]. J Intensive Care Med,2020,35(11):1203-1208. [61] WINTER W E,FLAX S D,HARRIS N S.Coagulation testing in the core laboratory[J]. Lab Med,2017,48(4):295-313. [62] SAMUELSON B T,CUKER A,SIEGAL D M,et al.Laboratory assessment of the anticoagulant activity of direct oral anticoagulants:a systematic review[J]. Chest,2017,151(1):127-138. [63] BARTOSZKO J,MARTINEZ-PEREZ S,CALLUM J,et al.Impact of cardiopulmonary bypass duration on efficacy of fibrinogen replacement with cryoprecipitate compared with fibrinogen concentrate:a post hoc analysis of the Fibrinogen Replenishment in Surgery (FIBRES) randomised controlled trial[J]. Br J Anaesth,2022,129(3):294-307. [64] BARTOSZKO J,KARKOUTI K.Managing the coagulopathy associated with cardiopulmonary bypass[J]. J Thromb Haemost,2021,19(3):617-632. [65] BIANCARI F,RUGGIERI V G,PERROTTI A,et al.Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery[J]. Heart Lung Circ,2019,28(12):1881-1887. [66] FITZGERALD J,LENIHAN M,CALLUM J,et al.Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery:a propensity score matched comparison to plasma[J]. Br J Anaesth,2018,120(5):928-934. [67] KARKOUTI K,BARTOSZKO J,GREWAL D,et al.Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery:a randomized pilot trial[J]. JAMA Netw Open,2021,4(4):e213936. [68] SMITH M M,SCHROEDER D R,NELSON J A,et al.Prothrombin complex concentrate vs plasma for post-cardiopulmonary bypass coagulopathy and bleeding:a randomized clinical trial[J]. JAMA Surg,2022,157(9):757-764. [69] VADLAMUDI R,CHAN J,SNIECINSKI R M.Catastrophic intracardiac thrombosis during emergency repair of an expanding aortic pseudoaneurysm:a case report[J]. A A Pract,2019,13(9):342-345. [70] SCHMIDT D E,CHAIRETI R,BRUZELIUS M,et al.Correlation of thromboelastography and thrombin generation assays in warfarin-treated patients[J]. Thromb Res,2019,178:34-40. [71] PONSCHAB M,VOELCKEL W,PAVELKA M,et al.Effect of coagulation factor concentrate administration on ROTEM® parameters in major trauma[J]. Scand J Trauma Resusc Emerg Med,2015,23:84. [72] ISLAM R,KUNDU S,JHA S B,et al.Cirrhosis and coagulopathy:mechanisms of hemostasis changes in liver failure and their management[J]. Cureus,2022,14(4):e23785. [73] LISMAN T,PORTE R J.Rebalanced hemostasis in patients with liver disease:evidence and clinical consequences[J]. Blood,2010,116(6):878-885. [74] CHOW J H,LEE K,ABUELKASEM E,et al.Coagulation management during liver transplantation:use of fibrinogen concentrate,recombinant activated factor VⅡ,prothrombin complex concentrate,and antifibrinolytics[J]. Semin Cardiothorac Vasc Anesth,2018,22(2):164-173. [75] BLASI A,PATEL V C,SPANKE E N H E,et al. Fibrin clot quality in acutely ill cirrhosis patients:relation with outcome and improvement with coagulation factor concentrates[J]. Liver Int,2022,42(2):435-443. [76] LORENZ R,KIENAST J,OTTO U,et al.Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage[J]. Eur J Gastroenterol Hepatol,2003,15(1):15-20. [77] DREBES A,DE VOS M,GILL S,et al.Prothrombin complex concentrates for coagulopathy in liver disease:single-center,clinical experience in 105 patients[J]. Hepatol Commun,2019,3(4):513-524. [78] HUANG W T,CANG W C,DERRY K L,et al.Four-factor prothrombin complex concentrate for coagulopathy reversal in patients with liver disease[J]. Clin Appl Thromb,2017,23(8):1028-1035. [79] TISCHENDORF M,FUCHS A,ZEUZEM S,et al.Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events[J]. J Hepatol,2019,70(4):800-801. [80] SØRENSEN B,SPAHN D R,INNERHOFER P,et al. Clinical review:Prothrombin complex concentrates—evaluation of safety and thrombogenicity[J]. Crit Care,2011,15(1):201. [81] KAWANAKA H,AKAHOSHI T,KINJO N,et al.Impact of antithrombin Ⅲ concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism[J]. Ann Surg,2010,251(1):76-83. [82] BULUT Y,SAPRU A,ROACH G D.Hemostatic balance in pediatric acute liver failure:epidemiology of bleeding and thrombosis,physiology,and current strategies[J]. Front Pediatr,2020,8:618119. [83] TRIPODI A,SALERNO F,CHANTARANGKUL V,et al.Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests[J]. Hepatology,2005,41(3):553-558. [84] KLEINVELD D J B,HAMADA S R,SANDRONI C. Trauma-induced coagulopathy[J]. Intensive Care Med,2022:1-4. [85] DEBOT M,SAUAIA A,SCHAID T,et al.Trauma-induced hypocalcemia[J]. Transfusion,2022,62(Suppl 1):S274-S280. [86] HOLCOMB J B,TILLEY B C,BARANIUK S,et al.Transfusion of plasma,platelets,and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma:the PROPPR randomized clinical trial[J]. JAMA,2015,313(5):471-482. [87] ZEESHAN M,HAMIDI M,FEINSTEIN A J,et al.Four-factor prothrombin complex concentrate is associated with improved survival in trauma-related hemorrhage:a nationwide propensity-matched analysis[J]. J Trauma Acute Care Surg,2019,87(2):274-281. [88] INNERHOFER P,FRIES D,MITTERMAYR M,et al.Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC):a single-centre,parallel-group,open-label,randomised trial[J]. Lancet Haematol,2017,4(6):e258-e271. [89] STUBBS J R,TRAN S A,EMERY R L,et al.Cold platelets for trauma-associated bleeding:regulatory approval,accreditation approval,and practice implementation-just the “tip of the iceberg”[J]. Transfusion,2017,57(12):2836-2844. [90] ROSSAINT R,BOUILLON B,CERNY V,et al. The European guideline on management of major bleeding and coagulopathy following trauma:fourth edition[J]. Crit Care,2016,20(100. [91] KAO T W,LEE Y C,CHANG H T.Prothrombin complex concentrate for trauma induced coagulopathy:a systematic review and meta-analysis[J]. J Acute Med,2021,11(3):81-89. [92] MATSUSHIMA K,BENJAMIN E,DEMETRIADES D.Prothrombin complex concentrate in trauma patients[J]. Am J Surg,2015,209(2):413-417. [93] SCHÖCHL H,MAEGELE M,SOLOMON C,et al. Early and individualized goal-directed therapy for trauma-induced coagulopathy[J]. Scand J Trauma Resusc Emerg Med,2012,20:15. [94] SCHÖCHL H,VOELCKEL W,MAEGELE M,et al. Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate:a 7-day observational study of trauma patients[J]. Crit Care,2014,18(4):R147. |
| [1] | 褚宗棠, 王瑛, 赵莲, 周虹. 血红蛋白氧亲和力在临床应用的研究进展*[J]. 临床输血与检验, 2019, 21(2): 124-129. |
| [2] | 陈立,李忠俊. 如何构建我国治疗性血浆置换术的教学体系*[J]. 临床输血与检验, 2018, 20(3): 228-230. |
| [3] | 李文华,袁高洁,叶银,滕本秀,李忠俊,冉茜. 血浆置换床旁救治方案的建立及临床应用*[J]. 临床输血与检验, 2018, 20(3): 231-234. |
| [4] | 徐思璞, 费广鹤. 肺癌生物标志物的研究进展*[J]. 临床输血与检验, 2018, 20(2): 221-224. |
| [5] | 李双, 谢毓滨. 2009~2014年RhD阴性稀有血型献血者队伍建设及采供保障*[J]. 临床输血与检验, 2016, 18(3): 229-232. |
| [6] | 范金波,曹涛,彭娟,刘久波. 259例贮存式自身输血在妇科患者中的应用分析[J]. 临床输血与检验, 2016, 18(2): 108-110. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
